Hims & Hers Health, Inc. (NASDAQ:HIMS) reported a set of insider transactions by Chief Financial Officer Oluyemi Okupe on March 20, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows that Okupe sold 9,217 shares of the company’s Class A Common Stock for approximately $219,066. The sale prices ranged from $23.73 to $23.92 per share. In the same filing, Okupe also exercised stock options to acquire 4,489 shares at an exercise price of $5.01, for an aggregate exercise cost of $22,489.
Both the sale and the option exercise were completed under a Rule 10b5-1 trading plan that Okupe adopted on May 21, 2025. After the transactions reported on March 20, Okupe directly holds 318,789 shares of Hims & Hers Class A Common Stock. The filing also notes that 7,853 additional shares are held indirectly in the Oluyemi Okupe Separate Property Trust.
These insider moves come alongside a series of company developments that have captured investor attention. Hims & Hers announced a collaboration with Novo Nordisk that permits the company to sell commercially available doses of Ozempic and Wegovy as part of its weight loss care strategy. The partnership also coincided with Novo Nordisk withdrawing its legal action against Hims & Hers.
Market responses have been pronounced. Bank of America Securities revised its rating on the stock from Underperform to Neutral and raised its price target to $23.00. Shares have surged dramatically, with the company posting a 64% gain over the past week - its best weekly performance on record.
On the corporate leadership front, Hims & Hers has appointed Kathryn Beiser as Chief Communications Officer to oversee communications as the company pursues both domestic and international expansion.
The Form 4 filing provides the formal disclosure of Okupe’s transactions and current holdings; the other items noted in company disclosures and analyst commentary describe a broader set of strategic moves and market reactions that have contributed to heightened investor interest.
Note on scope: The article reports the transactions and the company developments exactly as disclosed in filings and company announcements. It does not introduce additional facts beyond those reported in the filings and company statements.